TWIST BIOSCIENCE CORP

Twist Bioscience sees a buy‑rating surge as analysts lift price targets to $89‑$90, citing a robust pipeline and growth in synthetic DNA, genome engineering, and biodefense.

Twist Bioscience Corporation, a San Francisco-based biotechnology company, is a leading player in synthetic DNA technology, offering innovative solutions for a range of applications including healthcare, biodefense, and data storage.

Twist Bioscience Corp, a biotechnology company specializing in synthetic DNA, reported mixed Q3 financial results, but analysts project revenue growth and a reduction in losses for the full fiscal year.

Twist Bioscience Corporation has reported a mixed Q2 2025 financial performance, but a strategic spin-off of its DNA data storage technology into Atlas Data Storage is expected to unlock value and accelerate innovation in the biotech sector.

Twist Bioscience Corp has reported a 22.16% increase in revenue, but faces ongoing challenges in achieving profitability, amidst a strategic spin-off of its data storage division, Atlas Data Storage, into an independent entity.